142 related articles for article (PubMed ID: 20647545)
21. Hydrogen sulphide-releasing diclofenac derivatives inhibit breast cancer-induced osteoclastogenesis in vitro and prevent osteolysis ex vivo.
Frantzias J; Logan JG; Mollat P; Sparatore A; Del Soldato P; Ralston SH; Idris AI
Br J Pharmacol; 2012 Mar; 165(6):1914-1925. PubMed ID: 21955294
[TBL] [Abstract][Full Text] [Related]
22. Epoxyeicosanoids suppress osteoclastogenesis and prevent ovariectomy-induced bone loss.
Guan H; Zhao L; Cao H; Chen A; Xiao J
FASEB J; 2015 Mar; 29(3):1092-101. PubMed ID: 25466887
[TBL] [Abstract][Full Text] [Related]
23. A comparison between the effects of hydrophobic and hydrophilic statins on osteoclast function in vitro and ovariectomy-induced bone loss in vivo.
Hughes A; Rogers MJ; Idris AI; Crockett JC
Calcif Tissue Int; 2007 Nov; 81(5):403-13. PubMed ID: 17982704
[TBL] [Abstract][Full Text] [Related]
24. The effects of luteolin on osteoclast differentiation, function in vitro and ovariectomy-induced bone loss.
Kim TH; Jung JW; Ha BG; Hong JM; Park EK; Kim HJ; Kim SY
J Nutr Biochem; 2011 Jan; 22(1):8-15. PubMed ID: 20233653
[TBL] [Abstract][Full Text] [Related]
25. Hederagenin protects mice against ovariectomy-induced bone loss by inhibiting RANKL-induced osteoclastogenesis and bone resorption.
Tian K; Su Y; Ding J; Wang D; Zhan Y; Li Y; Liang J; Lin X; Song F; Wang Z; Xu J; Liu Q; Zhao J
Life Sci; 2020 Mar; 244():117336. PubMed ID: 31972206
[TBL] [Abstract][Full Text] [Related]
26. Ebselen Is a Potential Anti-Osteoporosis Agent by Suppressing Receptor Activator of Nuclear Factor Kappa-B Ligand-Induced Osteoclast Differentiation In vitro and Lipopolysaccharide-Induced Inflammatory Bone Destruction In vivo.
Baek JM; Kim JY; Yoon KH; Oh J; Lee MS
Int J Biol Sci; 2016; 12(5):478-88. PubMed ID: 27019631
[TBL] [Abstract][Full Text] [Related]
27. Anacardic acid inhibits RANKL-induced osteoclastogenesis
Zhao K; Jia Y; Peng J; Pang C; Zhang T; Han W; Jiang J; Lu X; Zhu J; Qian Y
FASEB J; 2019 Aug; 33(8):9100-9115. PubMed ID: 31050917
[TBL] [Abstract][Full Text] [Related]
28.
Lee J; Ahn SH; Chen Z; Kang S; Choi DK; Moon C; Min SH; Park BJ; Lee TH
Molecules; 2020 Oct; 25(20):. PubMed ID: 33096734
[TBL] [Abstract][Full Text] [Related]
29. Targeting IKK/NF-κB pathway reduces infiltration of inflammatory cells and apoptosis after spinal cord injury in rats.
Han X; Lu M; Wang S; Lv D; Liu H
Neurosci Lett; 2012 Mar; 511(1):28-32. PubMed ID: 22289688
[TBL] [Abstract][Full Text] [Related]
30. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts.
Kneissel M; Luong-Nguyen NH; Baptist M; Cortesi R; Zumstein-Mecker S; Kossida S; O'Reilly T; Lane H; Susa M
Bone; 2004 Nov; 35(5):1144-56. PubMed ID: 15542040
[TBL] [Abstract][Full Text] [Related]
31. Harmine, a β-carboline alkaloid, inhibits osteoclast differentiation and bone resorption in vitro and in vivo.
Yonezawa T; Hasegawa S; Asai M; Ninomiya T; Sasaki T; Cha BY; Teruya T; Ozawa H; Yagasaki K; Nagai K; Woo JT
Eur J Pharmacol; 2011 Jan; 650(2-3):511-8. PubMed ID: 21047508
[TBL] [Abstract][Full Text] [Related]
32. Artemisia annua extract prevents ovariectomy-induced bone loss by blocking receptor activator of nuclear factor kappa-B ligand-induced differentiation of osteoclasts.
Lee SK; Kim H; Park J; Kim HJ; Kim KR; Son SH; Park KK; Chung WY
Sci Rep; 2017 Dec; 7(1):17332. PubMed ID: 29230013
[TBL] [Abstract][Full Text] [Related]
33. A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.
Kalyanaraman H; Ramdani G; Joshua J; Schall N; Boss GR; Cory E; Sah RL; Casteel DE; Pilz RB
J Bone Miner Res; 2017 Jan; 32(1):46-59. PubMed ID: 27391172
[TBL] [Abstract][Full Text] [Related]
34. SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-kappaB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth.
Feng R; Anderson G; Xiao G; Elliott G; Leoni L; Mapara MY; Roodman GD; Lentzsch S
Blood; 2007 Mar; 109(5):2130-8. PubMed ID: 17095620
[TBL] [Abstract][Full Text] [Related]
35. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
[TBL] [Abstract][Full Text] [Related]
36. In vitro and ex vivo evidence that estrogens suppress increased bone resorption induced by ovariectomy or PTH stimulation through an effect on osteoclastogenesis.
Most W; Schot L; Ederveen A; van der Wee-Pals L; Papapoulos S; Löwik C
J Bone Miner Res; 1995 Oct; 10(10):1523-30. PubMed ID: 8686508
[TBL] [Abstract][Full Text] [Related]
37. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
38. The naturally derived small compound Osthole inhibits osteoclastogenesis to prevent ovariectomy-induced bone loss in mice.
Zhao D; Wang Q; Zhao Y; Zhang H; Sha N; Tang D; Liu S; Lu S; Shi Q; Zhang Y; Dong Y; Wang Y; Shu B
Menopause; 2018 Dec; 25(12):1459-1469. PubMed ID: 29944638
[TBL] [Abstract][Full Text] [Related]
39. Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss.
Zhang Y; Guan H; Li J; Fang Z; Chen W; Li F
Sci Rep; 2015 Sep; 5():13575. PubMed ID: 26338477
[TBL] [Abstract][Full Text] [Related]
40. Catalpol suppresses osteoclastogenesis and attenuates osteoclast-derived bone resorption by modulating PTEN activity.
Meng J; Zhang W; Wang C; Zhang W; Zhou C; Jiang G; Hong J; Yan S; Yan W
Biochem Pharmacol; 2020 Jan; 171():113715. PubMed ID: 31751538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
